Iminoglycinuria is a rare genetic condition that affects how the kidneys reabsorb certain amino acids. Many people with Iminoglycinuria have no symptoms and feel well throughout life. Some may have mild features like increased glycine, proline, and hydroxyproline in the urine, and occasional digestive upset in infancy. It is lifelong, usually noticed in childhood or on routine urine testing, and serious complications are uncommon. Most people do not need treatment, though nutrition guidance and monitoring in childhood can help, and the outlook is generally very good.
Overview
IminoglycinuriaSymptoms
Most people with iminoglycinuria have no symptoms. It’s usually found on urine tests showing extra glycine and related amino acids; rarely, some may have mild feeding issues in infancy, slower growth, or kidney stone risk.
Outlook and prognosis
Most people with iminoglycinuria lead healthy lives, and many have no day‑to‑day symptoms. The condition mainly affects how the kidneys handle certain amino acids, so routine care focuses on hydration, balanced nutrition, and monitoring. Children often outgrow early feeding or growth concerns.
Causes and risk factors
Iminoglycinuria stems from inherited changes in kidney amino acid transporters, usually autosomal recessive. Risk is higher with family history or parental relatedness; non-genetic factors seldom cause it, though hydration, diet, or medicines can influence urine findings, not the underlying cause.
Genetic influences
Genetics are central in Iminoglycinuria: inherited changes affect kidney transporters that reabsorb glycine and related amino acids. Most cases follow autosomal recessive patterns; rare dominant or compound effects occur. Variants can influence severity, from silent findings to mild symptoms.
Diagnosis
Doctors suspect iminoglycinuria when urine amino acid testing shows high glycine, proline, and hydroxyproline. Diagnosis is confirmed with repeat urine studies, kidney function review, and genetic tests; many labs describe this as the genetic diagnosis of iminoglycinuria.
Treatment and drugs
Care focuses on easing symptoms of Iminoglycinuria and monitoring overall health. Many need no medicine; when issues arise, clinicians may address dehydration risk, kidney stones, or growth concerns, and review medications to avoid ones that raise urine amino acids. Genetic counseling helps families.
Symptoms
Most people feel completely well, and this is often found on a urine test rather than through noticeable signs. Iminoglycinuria is a rare inherited condition that changes how the kidneys handle a few small amino acids. Clinicians call this aminoaciduria, which means higher levels of these amino acids show up in urine instead of being reabsorbed. When early features of Iminoglycinuria do appear, they tend to be subtle and tied to lab results, not daily life.
Many living with Iminoglycinuria feel completely well with no day-to-day issues. It’s usually found by laboratory testing rather than because of complaints.
A urine test shows higher amounts of glycine, proline, and hydroxyproline. These are filtered by the kidneys but not fully taken back up in Iminoglycinuria.
Most children and adults grow, learn, and develop as expected. Energy levels and appetite are typically unaffected.
The condition is commonly noticed during testing done for unrelated health checks. Results can look unusual even when you feel well.
How people usually first notice Iminoglycinuria?
Many families first notice something is different when a baby has unusually sweet‑smelling urine and mild feeding issues, or a toddler has frequent, unexplained episodes of vomiting and dehydration during common illnesses. Doctors often pick it up after a routine urine test shows high levels of certain amino acids (imino acids and glycine) without other signs of kidney disease, prompting questions about the first signs of iminoglycinuria and how iminoglycinuria is first noticed. In some cases, it’s found through newborn screening panels or follow‑up testing in siblings after one child is diagnosed.
Types of Iminoglycinuria
Iminoglycinuria is a rare genetic condition that affects how the kidneys reabsorb certain small amino acids, which then spill into urine. Researchers describe several variants based on which transporters are affected and whether only the kidneys or both kidneys and intestines are involved. Symptoms don’t always look the same for everyone. Here are the main types to know about:
Benign variant
People have high levels of imino acids and glycine in urine but feel well. Most have no day‑to‑day symptoms and it’s often found on routine urine testing. This is the most common among the types of iminoglycinuria.
Renal‑only variant
The kidney transporter is mainly affected, so losses show up in urine while gut absorption is mostly normal. Many feel fine, though some children may have feeding issues or mild growth concerns. Doctors may monitor nutrition if urine losses are significant.
Renal‑intestinal variant
Both kidney reabsorption and intestinal uptake are reduced, so more amino acids are lost and less absorbed from food. Babies may have trouble gaining weight, loose stools, or low energy during illnesses. Early diet support can help maintain growth.
Secondary (transient) infant form
Seen in some newborns due to immature kidney transport that improves as the kidneys mature. Urine findings can look like iminoglycinuria at first but fade over months. Follow‑up testing helps confirm that it resolves over time.
What genetics can tell you about symptoms
Some people with iminoglycinuria have no symptoms, while others develop kidney stone pain or frequent urination because their kidneys don’t reabsorb certain amino acids well. Variants in SLC6A18 or SLC6A19 change kidney transport proteins, leading to excess glycine, proline, and hydroxyproline in urine.
Causes and risk factors
Iminoglycinuria is caused by inherited changes in genes that help the kidneys reabsorb glycine, proline, and hydroxyproline.
It is usually passed on in an autosomal recessive way, so a child is affected only when both parents carry the change without symptoms.
Having a gene change doesn’t mean you’ll definitely develop the condition.
Family history is the main risk factor for Iminoglycinuria, and the chance is higher when parents are closely related.
There are no known environmental or lifestyle causes, though general health factors can influence test results and how noticeable it is.
Environmental and biological risk factors
Many people want to know what might raise the chances of iminoglycinuria aside from fixed, inborn factors. Doctors often group risks into internal (biological) and external (environmental). For this condition, environmental risk factors for iminoglycinuria have not been shown to play a meaningful role, and other body-related factors appear limited based on current evidence. Here’s what research has and hasn’t linked to higher likelihood.
Everyday exposures to heavy metals, solvents, or pesticides have not been shown to increase the likelihood of iminoglycinuria. Evidence to date does not support these exposures as causes. Plenty of people with similar exposures live without developing the condition.
Common maternal conditions such as diabetes, high blood pressure, thyroid disease, or infections have not been linked to higher risk. Managing these conditions supports overall pregnancy health, but they do not appear to change the chances of this diagnosis.
Typical medical imaging or occupational radiation kept within safety limits has not been associated with this condition. Standard prenatal diagnostic radiation doses have not been shown to raise risk.
Being born early does not cause iminoglycinuria, but immature kidneys can briefly spill amino acids and mimic it on tests. Follow-up testing as the kidneys mature helps clarify a true diagnosis of iminoglycinuria.
Genetic risk factors
The pattern often runs in families when both copies of certain kidney transporter genes carry changes. In Iminoglycinuria, genetic risk factors for Iminoglycinuria center on transporters that move proline and glycine, with SLC6A20 most often affected. Some families have changes in more than one gene at the same time, which can shape how noticeable the urine findings are. Risk is not destiny—it varies widely between individuals.
Two altered copies: Iminoglycinuria usually appears when both copies of a relevant gene are changed. If each parent is a carrier, each pregnancy has a 25% chance of an affected child. Carriers are typically healthy.
SLC6A20 variants: Changes in this kidney transporter reduce reuptake of imino acids and glycine. Having changes in both gene copies commonly leads to classic Iminoglycinuria. A single changed copy may cause only mild lab findings.
Other transporter genes: Variants in related transport genes, such as SLC36A2, can also contribute. In some families these act alongside SLC6A20 to produce the full pattern. Gene combinations help explain differences between relatives.
Variable expression: The same inherited change can lead to different degrees of amino acid loss. Some have only a small glycine spill, while others meet criteria for Iminoglycinuria. Test results can vary even within one family.
Carrier findings: People with one altered copy may show a small rise in glycine or imino acids on urine testing. This does not usually cause symptoms. It does signal a higher chance of having a child with Iminoglycinuria if a partner is also a carrier.
Family history: Having a sibling or parent with Iminoglycinuria raises the likelihood of being a carrier. Targeted genetic testing can clarify who carries which variant. This can help with planning and early checks in relatives.
Parental relatedness: When parents are related by blood, they are more likely to share the same rare variant. This increases the odds of a child inheriting two altered copies. The condition itself behaves the same regardless of relatedness.
Lifestyle risk factors
Iminoglycinuria is a genetic condition; lifestyle habits do not cause it, but they can influence urine concentration and kidney comfort. Here is how lifestyle affects Iminoglycinuria, focusing on practical choices that can modify symptoms or complications. These points highlight lifestyle risk factors for Iminoglycinuria that may amplify urinary imino acid and glycine losses or strain the kidneys.
Consistent, adequate fluid intake helps dilute urine so imino acids and glycine are less concentrated. This may reduce urinary irritation and the chance of crystallization from concentrated solutes.
Very high-protein meals can temporarily raise filtered amino acids, increasing their urinary loss in iminoglycinuria. Spreading protein across meals may reduce peaks in excretion.
Collagen/gelatin products are rich in proline and hydroxyproline, which are lost in this condition. Heavy use may exaggerate urinary imino acid losses and confound monitoring without providing clear benefit.
Excess sodium can increase urinary calcium and overall solute load, which may compound kidney workload alongside persistent aminoaciduria. Moderating salt may ease kidney handling of solutes.
Risk prevention
Iminoglycinuria is a genetic condition where the kidneys spill certain small amino acids into urine; most people feel well and never need treatment. You can’t prevent the condition itself, but you can lower the chance of problems and support healthy growth. Early symptoms of iminoglycinuria are often absent, so simple check-ins can help catch issues like poor weight gain or dehydration during illnesses. Talk to your doctor about which preventive steps are right for you.
A genetics visit can explain how iminoglycinuria is inherited and your chances of passing it on. This helps with planning future pregnancies.
If iminoglycinuria runs in the family, relatives can consider carrier testing. Knowing carrier status can guide family planning and prenatal options.
People who both carry related gene changes can explore options like preimplantation genetic testing or prenatal testing. This can reduce the chance of having a child with iminoglycinuria.
Regular pediatric checkups can track growth, feeding, and development in children with iminoglycinuria. Early supports can be added if a delay or feeding issue appears.
Transmission
Iminoglycinuria is a genetic condition and is not contagious—it can’t be caught from someone or spread through everyday contact. The genetic transmission of iminoglycinuria usually follows an autosomal recessive pattern. This means a child needs two non-working copies of the gene, one from each parent, who are typically healthy carriers without symptoms. If both parents are carriers, each pregnancy has a 25% (1 in 4) chance of a child with iminoglycinuria, a 50% (1 in 2) chance of a carrier child, and a 25% chance of a child with no altered copy. New changes in the gene can happen but are uncommon, so most families learn about how iminoglycinuria is inherited only after carrier testing or a child’s diagnosis.
When to test your genes
Consider genetic testing if you had newborn screening or urine tests showing high glycine/proline/hydroxyproline, if a close relative has iminoglycinuria, or if your child has unexplained aminoaciduria. Testing can confirm the diagnosis, guide monitoring for kidney stone risk, and inform family planning. A genetics professional can help choose the right test and interpret results.
Diagnosis
Iminoglycinuria is usually found when routine urine testing picks up unusually high levels of certain amino acids, even though most people feel well. A careful review of symptoms, kidney health, and family background helps doctors decide which tests to order next. Many people feel relief just knowing what’s really going on. The diagnosis of Iminoglycinuria is confirmed by lab patterns and, when needed, genetic testing.
Most people have no symptoms, or only mild concerns like frequent urination or bedwetting in childhood. Doctors look for a pattern that fits a harmless kidney transport quirk rather than a broader kidney problem. Notes from growth and development can add context.
A urine study shows high glycine, proline, and hydroxyproline spilling into the urine. Other amino acids are usually normal or only slightly raised. This pattern points toward Iminoglycinuria rather than a generalized kidney tubule disorder.
Blood levels of glycine and imino acids are typically normal. This helps separate Iminoglycinuria from conditions where these amino acids build up in the bloodstream. Normal blood values alongside high urine levels support the diagnosis.
Basic kidney tests, including blood creatinine and a standard urinalysis, are usually normal. Finding normal kidney function helps rule out Fanconi syndrome and other causes of widespread amino acid loss. Imaging is rarely needed unless other problems are suspected.
Stages of Iminoglycinuria
Iminoglycinuria does not have defined progression stages. It’s typically a stable, lifelong difference in how the kidneys handle certain amino acids, and it’s usually identified by urine testing rather than a pattern of gradual change—there are often no early symptoms of Iminoglycinuria. Diagnosis is based on finding increased levels of specific amino acids in the urine; genetic testing may be offered to clarify certain risks. Many people feel reassured knowing what their tests can—and can’t—show.
Outlook and prognosis
Daily life with iminoglycinuria varies. Some people first notice frequent, loose stools in infancy, diaper rashes that don’t clear easily, or poor weight gain; others have no clear early symptoms of iminoglycinuria and only learn about it after urine testing. Everyone’s journey looks a little different. Most children grow and develop normally, and the condition often becomes less noticeable with age as the gut and kidneys mature. The small risk to watch for is dehydration if diarrhea is persistent, especially during infections or hot weather.
Here’s what research and experience suggest about the future. For the majority, iminoglycinuria is considered benign, with normal life expectancy and no organ damage. Rare reports describe feeding struggles or slower growth early on, but these usually improve with simple nutrition support and hydration. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle. Serious complications are uncommon; hospital care is rarely needed unless dehydration develops.
Looking at the long-term picture can be helpful. With routine care and attention to fluids, many people with iminoglycinuria lead active, healthy lives without daily limitations. If a child has ongoing digestive symptoms, a pediatrician or dietitian can help tailor meals and fluids to reduce stool losses and support growth. Talk with your doctor about what your personal outlook might look like.
Long-term effects
Iminoglycinuria is a genetic difference in how the kidneys handle certain small amino acids, so more of them spill into the urine over a lifetime. Most people feel well and do not notice day‑to‑day problems, and kidney function remains normal. It’s important to remember that “long-term” doesn’t always mean “progressive.” Doctors often find it on urine testing during a workup for something else, and early symptoms of iminoglycinuria are usually absent.
Extra glycine, proline, and similar amino acids continue to appear in the urine over time. In iminoglycinuria this pattern stays stable and does not typically signal organ damage.
Kidney function and structure usually remain normal over the years. People with iminoglycinuria are not known to have a higher risk of chronic kidney disease because of this condition.
Children and adults generally grow, learn, and live normally. Rare reports of developmental differences exist, but most people with iminoglycinuria do not have long-term health problems linked to it.
The condition tends to remain steady rather than worsening. Many living with iminoglycinuria never need treatment and continue routine life without kidney complications.
How is it to live with Iminoglycinuria?
Living with iminoglycinuria is usually quiet and uneventful, because most people have no symptoms and discover it only through urine testing that shows extra glycine, proline, and hydroxyproline being passed out. Day to day, it rarely limits activities, schooling, work, or exercise, though a few may notice mild issues like more frequent urination or need extra hydration during illness to feel their best. Family members often feel reassured once they learn it’s a benign inherited difference in kidney reabsorption, not kidney damage, and it doesn’t typically lead to complications. For many, the main impact is simply sharing this information with healthcare teams so it isn’t mistaken for a problem that requires treatment.
Treatment and drugs
Iminoglycinuria is usually mild and doesn’t need specific medication. Most people feel well; the condition mainly shows up on urine testing because the kidneys pass extra glycine and related compounds. Treatment plans often combine several approaches when needed: staying well hydrated, eating a balanced diet with regular protein but not excessive amounts, and checking growth and development in children. Supportive care can make a real difference in how you feel day to day, so your doctor may also look for and treat any unrelated issues that could cause fatigue, kidney stones, or dehydration. Ask your doctor about the best starting point for you, and whether periodic urine or blood checks make sense in your situation.
Non-drug treatment
Most people live normally day to day; care focuses on monitoring and practical support. Iminoglycinuria is usually benign, and early symptoms of iminoglycinuria are often minimal or absent. Non-drug treatments often lay the foundation for long-term health, emphasizing hydration, nutrition, development, and family support. Plans are tailored to age and any associated concerns.
Explains how the condition is inherited and the chance it could affect future children. Helps families consider testing options for siblings and future pregnancies.
Focuses on a balanced, age-appropriate diet without unnecessary amino acid supplements like glycine or proline. A dietitian can adjust plans if feeding concerns or growth issues come up.
Regular water intake supports kidney health and helps flush excess amino acids. Carrying a water bottle and sipping through the day can make this easier.
Periodic urine and blood checks track amino acids and kidney function. In iminoglycinuria, these snapshots help confirm things are stable over time.
Your genes may have an impact on how drugs work for you
Medicines that affect kidney transporters can work differently depending on your genes, because genetic variants change how strongly those transport “gates” move glycine and imino acids. Pharmacogenetic testing, when available, may guide dosing or drug choice to avoid side effects or poor response.
Pharmacological treatments
Most people with iminoglycinuria do not need daily medicines. There is no drug that corrects the underlying transporter issue, so treatment focuses on comfort and preventing complications if they arise. Drugs that target symptoms directly are called symptomatic treatments. Because early symptoms of iminoglycinuria are often mild or absent, medicines are typically used only if problems like kidney stones or urinary infections develop.
There is no approved medicine that fixes the amino acid transport problem in iminoglycinuria. Care usually centers on monitoring, hydration, and addressing issues like kidney stones if they occur.
This alkalinizing agent can reduce stone-forming crystals and is sometimes used to prevent recurrent kidney stones. Your doctor will adjust the dose based on urine testing and stone type.
This thiazide diuretic may be considered if calcium-based stones keep recurring despite other steps. It lowers urinary calcium, which can help reduce stone risk.
This alpha‑blocker can relax the ureter to help a small stone pass more easily. Not everyone responds to the same medication in the same way.
Genetic influences
Many people with iminoglycinuria feel well and only learn about it after a routine urine test shows extra glycine and related small molecules. The condition stems from inherited changes in genes that make transporter proteins in the kidney and intestine, which normally pull these compounds back into the body. Most cases follow an autosomal recessive pattern, meaning a child typically needs two gene changes—one from each parent—for iminoglycinuria to appear. A “carrier” means you hold the gene change but may not show symptoms. In some families, more than one gene can be involved, which helps explain why findings vary from person to person. Because of this variability, early symptoms of iminoglycinuria are often absent and day-to-day life is usually unaffected. Genetic testing can sometimes identify the underlying changes and inform family planning or testing of siblings.
Is Iminoglycinuria genetic?
Genetics are central in Iminoglycinuria: inherited changes affect kidney transporters that reabsorb glycine and related amino acids. Most cases follow autosomal recessive patterns; rare dominant or compound effects occur. Variants can influence severity, from silent findings to mild symptoms.
Pharmacogenetics—how genetics influence drug effects
Iminoglycinuria comes from inherited changes in kidney transporters that reabsorb glycine and related amino acids, so the condition itself usually doesn’t require medication. These differences generally don’t change how most prescription drugs are processed, because overall kidney filtering and the common drug transport systems used by many medicines remain intact. If a medicine is cleared mainly by the kidneys, drug dosing in people with iminoglycinuria is based on standard kidney function tests (like creatinine and eGFR) and how you respond, not on the genetic diagnosis. For example, if a child with iminoglycinuria needs a common antibiotic, the team follows usual dosing guidelines and monitors as they would for any child.
Genetic testing can sometimes identify how your body handles certain amino acids, but there aren’t specific pharmacogenetic dosing rules for iminoglycinuria. If you’re considering high-dose amino acid supplements (such as glycine or proline), check with your clinician first, since extra losses in urine may rise and benefits are uncertain. Overall, treatment decisions focus on monitoring and supportive care rather than drug–gene tailoring for iminoglycinuria.
Interactions with other conditions
Living with iminoglycinuria alongside another kidney or metabolic condition can blur what’s causing which symptom or lab change. Doctors call it a “comorbidity” when two conditions occur together. On its own, iminoglycinuria is usually mild and doesn’t lead to kidney damage, stones, or infections, but if someone also has a disorder that affects the kidney’s filtering tubes—such as a generalized amino acid loss—the combined effects can make dehydration, poor weight gain in infants, or unusual urine tests more likely. Because several kidney transport disorders involve related pathways, certain diseases may “overlap,” meaning urine amino acid patterns can look similar even when the conditions are different, which sometimes delays recognition of early symptoms of iminoglycinuria. The presence of another illness does not always mean iminoglycinuria will worsen, but it can change nutrition needs in babies and may prompt closer growth and hydration monitoring. Talk with your doctor about how your conditions may influence each other, especially if multiple specialists are involved.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described children who passed unusually sweet‑smelling urine and later learned it carried small amino acids that most kidneys normally reclaim. Families and communities once noticed patterns when more than one sibling was affected, hinting at something inherited long before genetics could explain it. Doctors observed that these children generally grew well and felt fine, which made the condition easy to overlook unless urine tests were done for other reasons.
First described in the medical literature as a problem with kidney “reabsorption” of certain building blocks of protein, Iminoglycinuria was initially recognized by careful urine chemistry rather than symptoms. Early reports focused on the consistent finding that glycine and imino acids such as proline and hydroxyproline spilled into the urine. Over time, descriptions became more precise, separating this harmless aminoaciduria from other kidney or metabolic conditions that can look similar but carry health risks.
With each decade, laboratory methods improved. Paper chromatography in the mid‑20th century gave way to modern amino acid profiling, confirming characteristic patterns in Iminoglycinuria. Researchers also noticed variability: some people had lifelong, pronounced amino acid loss; others had milder, transient findings in infancy that faded with age. This helped clinicians understand why many living with Iminoglycinuria feel well and why it is often found by chance.
Advances in genetics later clarified the picture. Studies linked Iminoglycinuria to changes in kidney transport “dimmer switches” that move glycine and imino acids from the forming urine back into the bloodstream. These genes work in the kidney’s filtering tubes, and inherited changes can reduce their efficiency. This genetic insight explained family clusters, why both kidneys are involved, and why blood levels usually remain normal despite extra loss in urine.
From early theories to modern research, the story of Iminoglycinuria shows how a quiet laboratory finding became a well‑defined, generally benign condition. Knowing the condition’s history helps explain today’s care: most people do not need treatment, but doctors may check for other causes of aminoaciduria in children and adults to be sure nothing more serious is going on. As testing has become more common in newborn screening follow‑up and kidney evaluations, Iminoglycinuria is recognized more often, and its long track record of good health outcomes provides reassurance for families.